Dual Receptor Targeting Ensures Uptake and Anticancer Efficacy of Low-Density Lipoprotein-Docosahexaenoic Acid Nanoparticles Across Breast Cancer Cell Subtypes
In summary, our studies have shown that malignant cell dependence upon cholesterol acquisition can be exploited for lipoprotein-based drug delivery to breast cancer cells. Furthermore, the capacity of LDL nanoparticles to target both LDLR and SR-B1 ensures this as an efficient drug delivery platform against breast cancer cells.
Authors
- Joseph L. Bower (ORCID: https://orcid.org/0000-0001-5949-2749)
- Russell A. DeBose‐Boyd (ORCID: https://orcid.org/0000-0002-7452-5227)
- Arnida Anwar
- Jaideep Chaudhary (ORCID: https://orcid.org/0000-0002-8793-4329)
- Ian R. Corbin (ORCID: https://orcid.org/0000-0001-6902-8034)
- Marc Schumacher (ORCID: https://orcid.org/0000-0002-5527-4215)
- Zhe Chen (ORCID: https://orcid.org/0000-0002-1668-4051)
Institutions
- Advanced Imaging Research (United States) (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/bctt.s554396
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00